- Home
- BEAM vs KMPR Comparison
BEAM vs KMPR Comparison
Compare BEAM & KMPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BEAM | KMPR |
|---|---|---|
| Founded | 2017 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | BEAM | KMPR |
|---|---|---|
| Price | $31.65 | $38.75 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 4 |
| Target Price | $46.00 | ★ $56.67 |
| AVG Volume (30 Days) | ★ 2.0M | 664.3K |
| Earning Date | 02-24-2026 | 02-09-2026 |
| Dividend Yield | N/A | ★ 3.31% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.89 |
| Revenue | $55,701,000.00 | ★ $4,845,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $26.52 | $5.16 |
| P/E Ratio | ★ N/A | $9.95 |
| Revenue Growth | N/A | ★ 4.45 |
| 52 Week Low | $13.53 | $33.91 |
| 52 Week High | $36.44 | $72.25 |
Technical Indicators
Market Signals| Indicator | BEAM | KMPR |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 41.20 |
| Support Level | $29.80 | $38.06 |
| Resistance Level | $35.34 | $39.02 |
| Average True Range (ATR) | 2.80 | 0.87 |
| MACD | 0.14 | -0.04 |
| Stochastic Oscillator | 55.79 | 33.33 |
Price Performance
Historical ComparisonAbout BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About KMPR Kemper Corporation
Kemper Corp is a diversified insurance company that provides services in property and casualty insurance, along with life and health insurance. The company's property and casualty segment offers personal and commercial lines for home and automotive products. The company conducts its operations through two operating segments: Specialty Property & Casualty Insurance, and Life Insurance.